BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/22/2014 2:48:00 PM | Browse: 1048 | Download: 808
Publication Name World Journal of Cardiology
Manuscript ID 8305
Country/Territory Switzerland
Received
2013-12-25 09:00
Peer-Review Started
2013-12-25 14:48
To Make the First Decision
2014-01-15 16:33
Return for Revision
2014-01-20 17:32
Revised
Second Decision
2014-03-18 15:02
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-03-18 15:26
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-03-27 00:54
Typeset the Manuscript
2014-05-28 09:34
Publish the Manuscript Online
2014-06-20 19:33
ISSN 1949-8462 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Cardiac & Cardiovascular Systems
Manuscript Type Review
Article Title Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity
Manuscript Source Invited Manuscript
All Author List Nicolas Vuilleumier, Fabrizio Montecucco and Oliver Hartley
Funding Agency and Grant Number
Funding Agency Grant Number
Swiss National Science Foundation 310030_140736 (to Dr. Vuilleumier N)
Swiss National Science Foundation 32003B_134963/1 (to Dr. Montecucco F)
Foundation “Gustave and Simone Prévot” to Dr. Montecucco F
Corresponding Author Dr. Nicolas Vuilleumier, MD, PD, Head of Laboratory Medicine Division, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland. nicolas.vuilleumier@hcuge.ch
Key Words Autoantibodies; Cardiovascular disease; Atherosclerosis; Apolipoprotein A-1; Autoimmunity; Biomarkers
Core Tip This review provides a comprehensive and critical analysis of the most recent basic research articles and clinical trials on the role of autoantibodies to apolipoprotein A-1 as biomarkers and potential mediators of cardiovascular diseases (CVD). Evidence from both in vitro and in vivo studies showed that anti-apolipoprotein A-1 IgG might have critical pro-atherosclerotic activities by activating immune cells to release pro-inflammatory mediators and proteases. In addition, these autoantibodies might increase heart rate and arrhythmias both in humans and animal models. These studies suggest a causal role of anti-apolipoprotein A-1 immunoglobulins of G class in CVD, indicating that those autoantibodies could potentially represent an emerging therapeutic target to better fight CVD.
Publish Date 2014-06-20 19:33
Citation Vuilleumier N, Montecucco F, Hartley O. Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity. World J Cardiol 2014; 6(5): 314-326
URL http://www.wjgnet.com/1949-8462/full/v6/i5/314.htm
DOI http://dx.doi.org/10.4330/wjc.v6.i5.314
Full Article (PDF) WJC-6-314.pdf
Full Article (Word) WJC-6-314.doc
Manuscript File 8305-Review.doc
Answering Reviewers 8305-Answering reviewers.pdf
Copyright License Agreement 8305-Copyright assignment.pdf
Peer-review Report 8305-Peer reviews.pdf
Scientific Editor Work List 8305-Scientific editor work list.doc